Completed PHASE1 INTERVENTIONAL NCT00744770

TMC278-TiDP6-C121: Drug-drug Interaction Trial to Investigate the Potential Interaction Between TMC278 25 mg Daily and Methadone, at Steady State.

A Phase I, Open-label, Single-sequence Drug-drug Interaction Trial in Subjects on Stable Methadone Maintenance Therapy, to Investigate the Potential Interaction Between TMC278 25 mg q.d. and Methadone, at Steady-state.

Sponsor: Tibotec Pharmaceuticals, Ireland

Conditions HIV

Interventions TMC278

Updated 5 times since 2017 Last updated: Apr 26, 2010 Started: Oct 31, 2008 Primary completion: Jun 30, 2009 Completion: Jun 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00744770, this PHASE1 trial focuses on HIV and remains completed. Sponsored by Tibotec Pharmaceuticals, Ireland, it has been updated 5 times since 2008, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Oct 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Tibotec Pharmaceuticals, Ireland

Data source: Tibotec Pharmaceuticals, Ireland

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.